Correlation Between Virax Biolabs and Pasithea Therapeutics

Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Pasithea Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Pasithea Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virax Biolabs Group and Pasithea Therapeutics Corp, you can compare the effects of market volatilities on Virax Biolabs and Pasithea Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Pasithea Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Pasithea Therapeutics.

Diversification Opportunities for Virax Biolabs and Pasithea Therapeutics

0.78

Correlation Coefficient

Virax Biolabs  Pasithea Therapeutics

Poor diversification

The 3 months correlation between Virax and Pasithea is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Pasithea Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pasithea Therapeutics and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Pasithea Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pasithea Therapeutics has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Pasithea Therapeutics go up and down completely randomly.

Pair Corralation between Virax Biolabs and Pasithea Therapeutics

Given the investment horizon of 90 days Virax Biolabs Group is expected to generate 0.9 times more return on investment than Pasithea Therapeutics. However, Virax Biolabs Group is 1.11 times less risky than Pasithea Therapeutics. It trades about -0.09 of its potential returns per unit of risk. Pasithea Therapeutics Corp is currently generating about -0.14 per unit of risk. If you would invest  206.00  in Virax Biolabs Group on December 29, 2024 and sell it today you would lose (82.00) from holding Virax Biolabs Group or give up 39.81% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Virax Biolabs Group  vs.  Pasithea Therapeutics Corp

Virax Biolabs Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pasithea Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Virax Biolabs and Pasithea Therapeutics

The main advantage of trading using opposite Virax Biolabs and Pasithea Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Pasithea Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pasithea Therapeutics will offset losses from the drop in Pasithea Therapeutics' long position.

The idea behind Virax Biolabs Group and Pasithea Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.